Ultragenyx Pharmaceutical/$RARE
1D1W1MYTD1Y5YMAX
Capital at risk
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
- Ticker
- $RARE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,371
- Headquarters
- Novato, United States
- Website
- www.ultragenyx.com
RARE Metrics
BasicAdvanced
$1.4B
-
-$5.83
0.31
-
Price and volume
Market cap
$1.4B
Beta
0.31
52-week high
$39.89
52-week low
$12.73
Average daily volume
4.8M
Financial strength
Current ratio
1.726
Quick ratio
1.407
Long term debt to equity
-3.965
Total debt to equity
-4.232
Interest coverage (TTM)
-6.47%
Profitability
EBITDA (TTM)
-465
Gross margin (TTM)
-20.78%
Net profit margin (TTM)
-81.73%
Operating margin (TTM)
-73.64%
Effective tax rate (TTM)
-0.69%
Revenue per employee (TTM)
$520,000
Management effectiveness
Return on assets (TTM)
-24.22%
Return on equity (TTM)
932.27%
Valuation
Price to revenue (TTM)
2.035
Price to book
-4.9
Price to tangible book (TTM)
-3.13
Price to free cash flow (TTM)
-2.953
Free cash flow yield (TTM)
-33.86%
Free cash flow per share (TTM)
-4.913
Growth
Revenue change (TTM)
17.51%
Earnings per share change (TTM)
5.55%
3-year revenue growth (CAGR)
21.19%
10-year revenue growth (CAGR)
190.07%
3-year earnings per share growth (CAGR)
-17.13%
10-year earnings per share growth (CAGR)
1.02%
What the Analysts think about RARE
Analyst ratings (Buy, Hold, Sell) for Ultragenyx Pharmaceutical stock.
Analyst projections of the future price of Ultragenyx Pharmaceutical stock.
Bulls say / Bears say
Ultragenyx reported Q2 2026 revenue of $214 million, a 28% year-over-year increase to a record high, driven by strong uptake across its rare disease portfolio (GlobeNewswire Reuters)
On August 19, 2026, the FDA granted accelerated approval for GENGLYCOS (pariglasgene brecaparvovec-opnr), Ultragenyx’s gene therapy for GSDIa, marking the first treatment addressing the underlying cause of the disease and expanding its commercial portfolio (FDA S&P Global)
Ultragenyx held $436 million in cash, cash equivalents, and marketable securities as of June 30, 2026, providing a solid financial runway to fund its pipeline through key upcoming readouts and launches (GlobeNewswire)
Shares plunged over 40% after the Phase 3 Aspire study of GTX-102 for Angelman syndrome failed to meet primary and secondary endpoints on September 3, 2026, underscoring significant pipeline binary risk (Reuters)
Ultragenyx’s net loss for Q2 2026 was $92 million ($0.90 per share), reflecting ongoing unprofitability despite record revenue growth (SEC)
Total operating expenses in Q2 2026 reached $289 million, surpassing revenues by $75 million and highlighting a high cost structure that may pressure future margins (SEC)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2026.
RARE Financial Performance
Revenues and expenses
RARE Earnings Performance
Company profitability
Upcoming events
No upcoming events
RARE News
AllArticlesVideos
Funds containing RARE
AllEURUSDGBP
Fund name | Fund size | $RARE weighting |
|---|---|---|
iShares Ageing Population€AGED | €822M | 0.12% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.10% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.10% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.05% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.